Biosensors   

Is Biosensors a good buy?

yawning, so slow..

XiaoMaGe888      ( Date: 09-May-2008 10:34) Posted: "XIOA" BIG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!COMING SOON!!!!!! 10:12:12 0.720 23,000 Buy Up 10:11:13 0.723 1,568,000 X 10:02:05 0.720 30,000 Buy Up 10:01:50 0.720 34,000 Sell Down 10:01:40 0.720 30,000 Sell Down 10:01:34 0.720 58,000 Sell Down 10:01:22 0.720 20,000 Sell Down 09:59:06 0.720 30,000 Sell Down 09:58:29 0.720 20,000 Sell Down 09:56:10 0.720 31,000 Sell Down 09:53:25 0.725 5,000 Buy Up 09:45:13 0.724 1,310,000 X

 

X = Married deal? So many X volume today, transacted volume so low. That means the X deals are not transacted thru the stock exchange right? Also, the price are not rounded up at half cent.

 

can anyone enlighten me what e 'x' trade means? thx alot.

 

 

11:46:15	0.715	10,000	Buy Up
11:43:26	0.715	13,000	Buy Up
11:42:41	0.722	1,864,000	X
11:32:56	0.715	14,000	Buy Up

 

 

 

 

may consider to buy in during show time. Can save 0.005 cts, he he. 

 

"XIOA" BIG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!COMING SOON!!!!!!

10:12:12	0.720	23,000	Buy Up
10:11:13	0.723	1,568,000	X
10:02:05	0.720	30,000	Buy Up
10:01:50	0.720	34,000	Sell Down
10:01:40	0.720	30,000	Sell Down
10:01:34	0.720	58,000	Sell Down
10:01:22	0.720	20,000	Sell Down
09:59:06	0.720	30,000	Sell Down
09:58:29	0.720	20,000	Sell Down
09:56:10	0.720	31,000	Sell Down
09:53:25	0.725	5,000	Buy Up
09:45:13	0.724	1,310,000	X

 

Price attractive leh! Ok, see 2morow how first. Do some averaging leow.

 

Latest BIG anouncements,

BIG has acquired the remaining 50% equity stake in JW ICU Medical Limited.

 

http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_BA7BCC410A74BC95482574430026B422/$file/Acquire_remaining50percent_of_JWICU.pdf?openelement

 

Ya, the ABT bifurcation system looks quite hopeless compared to Devax's.

Earlier on, a credit suisse analyst said he believed NOBORI royalty should close to 40% of sales. I believe after the recent US$40m cash advance payment, royalty has to reduced to around 30%. I think BIG's licensing deals structured in such a way with what the licensee can afford to pay. Eg: Guidant and Terumo have the cash and they paid multi-millions of cash for licensing deals. Xtent and Devax are small companies with not much cash, so they gave free shares to BIG and grant BIG share options as well. However, i don't think BIG will deal with Xtent and Devax at low royalty of sales of say 20% only. 5 years ago when they signed the licensing deals, this technology was BIG's latest and best and i don't think BIG will settle down for low royalties.  Both Xtent and Devax need to have a good DES using BiolimusA9 and PLA biodegradable polymer to sell. Sales of their DES will also drive the sales of their own delivery system which is their own in-house product. So, Xtent and Devax are aiming to make lesser on their DES, but keep all the profits from sales of their own in-house delivery system. Although both Xtent and Devax (uses their own Cobalt Chromium metal strut) are not copying exactly the same Biomatrix DES like what Terumo did for NOBORI (uses S-stent metal strut), i believe BIG should still be charging them 30 to 40% of sales royalties derived out from both Xtent and Devax's DES sales. Without the top class DES technology, Xtent and Devax will have problems selling their DES and their own in-house delivery system will also not be selling well. Their BiolimusA9 and PLA biodegradable polymer DES will be the key attraction and main driver to lead their sales and they need solid DES clinical trial results to attract people to use their whole system. But both licensees will make a killing selling their respective delivery systems. I think their delivery system is not cheap and they will charge a premium for it.

 

So easy to steam over biomatrix logo.. :-)

I think this two videos shows what BIG promise biosensors has..  

http://www.xtentinc.com/video.cfm

http://www.devax.net/animation.htm

The stent from Devax is suppose to address approximately 20 percent of patients treated for coronary artery disease..because these segment of people have lesions located at bifurcations. The Abbott Stent for this job does not look fantastic to me.. Only appears to expand on one of the arterial branches only. See http://www.abbottvascular.com/en_US/content/document/Frontier5steps.pdf

And Xtent is supposed to be addressing another niche segment with long lessions etc. Also improves stent apposition, without which ..leads to very late stent thrombosis. Note that some newer stents claim to prevent thrombosis with just using biocomptible coating..but this alone is not enough. There are many factors that could lead to thrombosis.. (see slide 3 in http://www.healthgrabber.com/sessions/select-grube.pdf). One major one is stent design.  

Even if Biosensors could get a 20% royalties from these guys when they are successful, it will be really fantastic.

 

Bo Li You after CE Mark and US$40m cash profit this stock still at 70cts. No more losses and huge profits start rolling in liao. Sometimes Mr Market can stay moody and irrational longer than we think. Maybe investors are still skeptical whether this company has finally turned around. Since a lot of investors / analysts are not interested / do not understand the significance of BIG's clinical trial results and patents, i believe we need one more profit related good news to set the share price on the right track.

 

Duno why they put it on the Biomatrix webpage. Not many investors will go to that webpage. The last time i went in and saw the CE Mark certificate serial number and bought 4D but bo tioh also. People normally go to biomatrix webpage when they need a stent. What kind of investor PR is this? Luckily the "Biomatrix" logo looks damn "chai". Just by looking at the logo also steam liao, i think got chance to sell well 

 

Thank You Bengster. Noted about the LEADER's trial and stand corrected. Btw you asked earlier about this-Biosensors is participating in the euroPCR on the 13-16 May 2008 in Barcelona , Spain. They announced this in their Biomatrix website

	Meet Biosensors...
	From the outset Biosensors has attached great importance to our presence at all the major international congresses as well as an active presence at local events. This ensures that we focus our energy and resources on developing the right products to effectively satisfy our customer needs, whilst our active presence at these events allows us to strengthen our relationship with customers and partners. Our presence in 2008: SINGLIVE - 7-9 March 2008, Singapore CIT - 19-23 March 2008, Beijing, China EuroPCR - 13-16 May, 2008, Barcelona, Spain SOLACI - 6-8 August 2008, Cancun, Mexico TCT - 12-17 October, Washington DC, USA Various Local Congresses

 

LEADERS results not out yet. Analysts expect LEADERS results to be announced on TCT 2008 in Oct 2008. NOBORI results were out in Oct 2007 and Biomatrix beat Taxus Liberte hands down. I heard even the key personnel in BIG are also shocked at the share price performance after NOBORI results, China JWMS subsidiary, CE Mark and US$40m cash. I also heard there is an European fund (Germany based) doing due-diligence on BIG now and has plans to buy up a significant portion of BIG's free float. China JWMS is worth US$0.8 to 1B and BIG should be worth US$2.5B at takeover was the initial assessment value that the European fund gave when they first looked at BIG. Lets hope they get the "green" light from their HQ to start buying soon. But these are just market hearsays, not to be based for your buying decisions. Buy at your own risk. Buy only when you believe in BIG's fundamentals and potential.

allright      ( Date: 08-May-2008 09:27) Posted: XMG888 I think you are so funny ...but fair I suppose.Hope you are right and the share price goes up.What i can't understand is whith the usd40m being received this month and the CE mark and the fact that the LEADER'S trials have been positive and the equivalent in US like Abbot are all going up WHY is it so LOW in SINGAPORE???????

 

when will e selling lose momentum...

 

XMG888 I think you are so funny ...but fair I suppose.Hope you are right and the share price goes up.What i can't understand is whith the usd40m being received this month and the CE mark and the fact that the LEADER'S trials have been positive and the equivalent in US like Abbot are all going up WHY is it so LOW in SINGAPORE???????

 

LP" BIG "Chiong!!!!!!!!!!!!!!!!!!

 

No doubt, still good buy at .70

 

At least OCBC got highlight the potential of the patent number: 6939376. This key patent will be a very useful weapon (i would say its a nuclear weapon) to wipe out all DES rivals, so i believe this patent is one of the key motivation for big DES boys to takeover BIG. It is very clear limus drug on biodegradable polymer is the future direction of DES technology. If JNJ buys over BIG and holds this key patent, i believe JNJ will dominate the DES market for the next 10 years.

 

Medical News Article on Patents

U.S. patent granted covering drug-eluting stent technology

2005 OCT 10 -- Biosensors International Group, Ltd., (BIG SP) said it was granted a patent from the U.S. Patent and Trademark Office covering the technology behind its drug-eluting stents (DES). Specifically, this U.S. patent, (Patent Number 6939376) covers the use of anti-restenotic, immuno-suppressive drugs including Everolimus, in combination with a biodegradable drug-release polymer coating on an endovascular stent. The patent was filed in April 2002, and is valid in the U.S. for 20 years from the filing date. The company has also filed for the same patent in Australia, Japan and Europe, which it is anticipating to receive.

---------------------------------------------------------------------------------------------------

Thursday, May 17, 2007

http://www.google.com/patents?id=9sYUAAAAEBAJ&dq=6939376